FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308139733> ?p ?o ?g. }

• W4308139733 endingPage "A30" @default.
• W4308139733 startingPage "A29" @default.
• W4308139733 abstract "Abstract Objectives Cortisol is known to promote adipocyte differentiation and maturation, and prolonged exposure to excess cortisol contributes to the development of obesity and metabolic dysregulation. The intracellular 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme catalyzes the conversion of inactive cortisone to active cortisol. Recently, we demonstrated reduced brain 11β-HSD1 levels in vivo with increasing body mass index (BMI), using positron emission tomography (PET) radioligands [11C]- and [18F]AS2471907(1). PET imaging can simultaneously quantify uptake in multiple organs (e.g., liver/brain). [18F]AS2471907 has high uptake and specific binding in the brain and liver(2). Liver and brain 11β-HSD1 measured by PET imaging may help elucidate the roles of cortisol activation in the setting of metabolic dysregulation. Thus, we performed PET imaging studies to examine 11β-HSD1 levels in the liver and brain. Methods Nine individuals (5F/4M) with a range of BMIs (22.6-34.4 kg/m2) underwent a 90 min PET/CT acquisition with arterial plasma sampling after injection of [18F]AS2471907. Regions-of-interest (ROI) for the liver were manually drawn on a summed PET image (60-90 min). Seventeen brain ROIs were selected from the anatomical automatic labeling (AAL) template and applied to the dynamic PET images to generate time-activity-curves (TACs). Brain volume of distribution (VT, mL/cm3), the target tissue to plasma ratio of radioligand at equilibrium, was estimated for each ROI using the multilinear analysis-1 method with plasma input function. Mean whole-brain VT values were calculated by averaging all ROIs. Given the appearance of irreversible kinetics in the liver, Ki (min-1), the rate of irreversible tracer uptake, was calculated using the Patlak method. Results Qualitative brain and liver uptake was assessed by examining a summed PET image (SUV 60-90min). The parent fraction in plasma was 88±1% at 90 min, indicating negligible plasma radiolabeled-metabolites contributing the measured signal in the liver. Kinetic modeling estimates demonstrated decreasing whole brain VT with increasing BMI (R2=0.53), similar to our previously published study examining only brain in a larger cohort(1). Patlak methods provided good estimates of Ki. In an opposite manner from the brain, correlations seen in the liver using Ki were positively correlated with BMI (R2=0.57). Conclusions These preliminary studies suggest obesity is associated with increased 11β-HSD1 levels in the liver but decreased 11β-HSD1 levels in the brain. Clinically, liver specific 11β-HSD1 inhibitors may prove beneficial in treating metabolic sequalae of obesity such non-alcoholic fatty liver disease (NAFLD) by inhibiting activity of higher 11β-HSD1 levels. Further studies in NAFLD and obesity are necessary to determine appropriate populations that would benefit from 11β-HSD1 inhibitors and longitudinal in vivo PET imaging to help inform development of future therapeutics. References [1] Bini, et al, Molecular Imaging and Biology, 2020. [2] Bini, et al, IEEE Trans on Radiation and Plasma Medical Sciences, 2021 Presentation: Saturday, June 11, 2022 1:42 p.m. - 1:47 p.m., Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4308139733 created "2022-11-08" @default.
• W4308139733 creator A5004932337 @default.
• W4308139733 creator A5005864631 @default.
• W4308139733 creator A5006508700 @default.
• W4308139733 creator A5012357230 @default.
• W4308139733 creator A5016003520 @default.
• W4308139733 creator A5026797171 @default.
• W4308139733 creator A5046219145 @default.
• W4308139733 creator A5054839216 @default.
• W4308139733 creator A5062263815 @default.
• W4308139733 creator A5072017477 @default.
• W4308139733 creator A5074621763 @default.
• W4308139733 date "2022-11-01" @default.
• W4308139733 modified "2023-10-14" @default.
• W4308139733 title "RF12 | PSUN106 Quantifying Liver and Brain Levels of 11β-hydroxysteroid Dehydrogenase Type 1 in Obesity Using Positron Emission Tomography Imaging" @default.
• W4308139733 doi "https://doi.org/10.1210/jendso/bvac150.062" @default.
• W4308139733 hasPublicationYear "2022" @default.
• W4308139733 type Work @default.
• W4308139733 citedByCount "0" @default.
• W4308139733 crossrefType "journal-article" @default.
• W4308139733 hasAuthorship W4308139733A5004932337 @default.
• W4308139733 hasAuthorship W4308139733A5005864631 @default.
• W4308139733 hasAuthorship W4308139733A5006508700 @default.
• W4308139733 hasAuthorship W4308139733A5012357230 @default.
• W4308139733 hasAuthorship W4308139733A5016003520 @default.
• W4308139733 hasAuthorship W4308139733A5026797171 @default.
• W4308139733 hasAuthorship W4308139733A5046219145 @default.
• W4308139733 hasAuthorship W4308139733A5054839216 @default.
• W4308139733 hasAuthorship W4308139733A5062263815 @default.
• W4308139733 hasAuthorship W4308139733A5072017477 @default.
• W4308139733 hasAuthorship W4308139733A5074621763 @default.
• W4308139733 hasBestOaLocation W43081397331 @default.
• W4308139733 hasConcept C126322002 @default.
• W4308139733 hasConcept C134018914 @default.
• W4308139733 hasConcept C150903083 @default.
• W4308139733 hasConcept C170493617 @default.
• W4308139733 hasConcept C185592680 @default.
• W4308139733 hasConcept C207001950 @default.
• W4308139733 hasConcept C2775842073 @default.
• W4308139733 hasConcept C2776791281 @default.
• W4308139733 hasConcept C2776914184 @default.
• W4308139733 hasConcept C2989005 @default.
• W4308139733 hasConcept C67847695 @default.
• W4308139733 hasConcept C71924100 @default.
• W4308139733 hasConcept C86803240 @default.
• W4308139733 hasConcept C87753298 @default.
• W4308139733 hasConceptScore W4308139733C126322002 @default.
• W4308139733 hasConceptScore W4308139733C134018914 @default.
• W4308139733 hasConceptScore W4308139733C150903083 @default.
• W4308139733 hasConceptScore W4308139733C170493617 @default.
• W4308139733 hasConceptScore W4308139733C185592680 @default.
• W4308139733 hasConceptScore W4308139733C207001950 @default.
• W4308139733 hasConceptScore W4308139733C2775842073 @default.
• W4308139733 hasConceptScore W4308139733C2776791281 @default.
• W4308139733 hasConceptScore W4308139733C2776914184 @default.
• W4308139733 hasConceptScore W4308139733C2989005 @default.
• W4308139733 hasConceptScore W4308139733C67847695 @default.
• W4308139733 hasConceptScore W4308139733C71924100 @default.
• W4308139733 hasConceptScore W4308139733C86803240 @default.
• W4308139733 hasConceptScore W4308139733C87753298 @default.
• W4308139733 hasIssue "Supplement_1" @default.
• W4308139733 hasLocation W43081397331 @default.
• W4308139733 hasLocation W43081397332 @default.
• W4308139733 hasOpenAccess W4308139733 @default.
• W4308139733 hasPrimaryLocation W43081397331 @default.
• W4308139733 hasRelatedWork W2170978964 @default.
• W4308139733 hasRelatedWork W2180392389 @default.
• W4308139733 hasRelatedWork W2326363362 @default.
• W4308139733 hasRelatedWork W2472578905 @default.
• W4308139733 hasRelatedWork W2748952813 @default.
• W4308139733 hasRelatedWork W2887708788 @default.
• W4308139733 hasRelatedWork W2910687904 @default.
• W4308139733 hasRelatedWork W3004998377 @default.
• W4308139733 hasRelatedWork W3112024422 @default.
• W4308139733 hasRelatedWork W3212964539 @default.
• W4308139733 hasVolume "6" @default.
• W4308139733 isParatext "false" @default.
• W4308139733 isRetracted "false" @default.
• W4308139733 workType "article" @default.